Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633133 | 0.81 | L3MBTL1 (0.37) | PPARAL3MBTL1HDAC1GAA | |
| SCHEMBL8968174 | 0.71 | SMN1; SMN2 (0.60) | L3MBTL1ALDH1A1HDAC1GAASMN1; SMN2 | |
| SCHEMBL2530176 | 0.71 | KCNA3 (0.50) | L3MBTL1ALDH1A1LTA4HGAAKDM4E | |
| SCHEMBL1925564 | 0.71 | PKM (0.67) | L3MBTL1ALDH1A1PKMTP53TSHR | |
| SCHEMBL21518358 | 0.69 | KCNA3 (0.48) | L3MBTL1ALDH1A1HDAC1LTA4HKDM4E | |
| SCHEMBL22119988 | 0.69 | FAAH (0.42) | L3MBTL1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL12321296 | 0.69 | L3MBTL1 (0.55) | PPARAL3MBTL1ALDH1A1PKMGAA | |
| SCHEMBL19024978 | 0.69 | GAA (0.58) | PPARAL3MBTL1LTA4HPKMGAA | |
| SCHEMBL2763189 | 0.68 | PLA2G4B (0.57) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL11278302 | 0.68 | THRB (0.56) | PPARAPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | PPARA 3811/4885L3MBTL1 3094/4885ALDH1A1 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.